FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
暂无分享,去创建一个
David M. Thomas | W. Sellers | K. Venkatesan | Christopher J. Wilson | J. Monahan | A. Kauffmann | F. Hofmann | T. Brümmendorf | C. García-echeverría | J. Borawski | V. Guagnano | Yao Yao | C. Stamm | Simon Wöhrle | D. Graus-Porta | Zhi Chen | L. Gaither | V. Bordas | A. Pornon | M. Ito | Yun Zhang | L. Barys | Fang Li | Mickaël Le Douget | D. Graus‐Porta | M. Ito
[1] M. Hidalgo,et al. Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors , 2012 .
[2] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[3] L. Desnoyers,et al. FGF19 and cancer. , 2012, Advances in experimental medicine and biology.
[4] Pascal Furet,et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. , 2011, Journal of medicinal chemistry.
[5] J. Wesche,et al. Fibroblast growth factors and their receptors in cancer. , 2011, The Biochemical journal.
[6] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[7] A. Peterson,et al. FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways , 2011, PloS one.
[8] Lincoln D. Stein,et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. , 2011, Cancer cell.
[9] P. Meltzer,et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. , 2011, Cancer research.
[10] I. Petersen,et al. Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.
[11] David M. Thomas,et al. Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis , 2010, Clinical Cancer Research.
[12] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[13] Hugo M. Horlings,et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets , 2009, Oncogene.
[14] L. Staudt,et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. , 2009, The Journal of clinical investigation.
[15] M. Meyerson,et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer , 2009, Cancer biology & therapy.
[16] J. D. Benson,et al. Single-vector inducible lentiviral RNAi system for oncology target validation , 2009, Cell cycle.
[17] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[18] Kristian Cibulskis,et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma , 2008, Proceedings of the National Academy of Sciences.
[19] A. Reiter,et al. Fibroblast Growth Factor Receptor and Platelet-Derived Growth Factor Receptor Abnormalities in Eosinophilic Myeloproliferative Disorders , 2008, Acta Haematologica.
[20] P. Furet,et al. Entry into a new class of protein kinase inhibitors by pseudo ring design. , 2008, Bioorganic & medicinal chemistry letters.
[21] A. Chase,et al. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. , 2007, Blood.
[22] P. Pollock,et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes , 2007, Oncogene.
[23] N. Itoh. The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease. , 2007, Biological & pharmaceutical bulletin.
[24] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[25] Des Powe,et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis , 2007, Breast Cancer Research.
[26] S. Levy,et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[27] Andrew D. Yates,et al. Somatic mutations of the protein kinase gene family in human lung cancer. , 2005, Cancer research.
[28] A. Wilkie. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. , 2005, Cytokine & growth factor reviews.
[29] T. Maeda,et al. Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML. , 2005, Blood.
[30] J. G. Park,et al. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. , 2001, Cancer research.
[31] O. Kallioniemi,et al. CGH, cDNA and Tissue Microarray Analyses Implicate FGFR2 Amplification in a Small Subset of Breast Tumors , 2001, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.
[32] M. Makuuchi,et al. Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. , 1999, Cancer research.
[33] D. Chopin,et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.
[34] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[35] K. Yanagihara,et al. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. , 1998, Laboratory investigation; a journal of technical methods and pathology.
[36] E. Schröck,et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.
[37] D. Amadori,et al. DNA amplification in human gastric carcinomas. , 1993, Cancer genetics and cytogenetics.
[38] H. Sakamoto,et al. Amplified genes in cancer in upper digestive tract. , 1993, Seminars in cancer biology.
[39] J. Yokota,et al. Isolation of an Amplified DNA Sequence in Stomach Cancer , 1990, Japanese journal of cancer research : Gann.